Does the media favor ABUS or LEGN?

In the previous week, Arbutus Biopharma had 1 more articles in the media than Legend Biotech. MarketBeat recorded 10 mentions for Arbutus Biopharma and 9 mentions for Legend Biotech. Arbutus Biopharma's average media sentiment score of 0.71 beat Legend Biotech's score of 0.29 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ABUS or VCYT?

Veracyte has higher revenue and earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arbutus Biopharma $14.08M 62.61 -$33.50M $0.79 5.63 Veracyte $517.15M 7.12 $66.35M $1.41 32.49

Does the media favor ABUS or VCYT?

In the previous week, Arbutus Biopharma had 3 more articles in the media than Veracyte. MarketBeat recorded 10 mentions for Arbutus Biopharma and 7 mentions for Veracyte. Arbutus Biopharma's average media sentiment score of 0.71 beat Veracyte's score of -0.05 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ABUS or XENE?

In the previous week, Xenon Pharmaceuticals had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 18 mentions for Xenon Pharmaceuticals and 10 mentions for Arbutus Biopharma. Xenon Pharmaceuticals' average media sentiment score of 0.90 beat Arbutus Biopharma's score of 0.71 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABUS or ACAD?

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 18 mentions for ACADIA Pharmaceuticals and 10 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.71 beat ACADIA Pharmaceuticals' score of -0.17 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Arbutus Biopharma (ABUS) Competitors

$4.44 -0.01 (-0.11%)

As of 10:09 AM Eastern

Compare

ABUS vs. RLAY, LEGN, VCYT, XENE, and ACAD

Should you buy Arbutus Biopharma stock or one of its competitors? Arbutus Biopharma's main competitors and comparable companies include Relay Therapeutics (RLAY), Legend Biotech (LEGN), Veracyte (VCYT), Xenon Pharmaceuticals (XENE), and ACADIA Pharmaceuticals (ACAD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arbutus Biopharma compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Relay Therapeutics presently has a consensus price target of $25.92, indicating a potential upside of 36.69%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential upside of 12.36%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relay Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arbutus Biopharma has a net margin of 84.22% compared to Relay Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Arbutus Biopharma	84.22%	90.98%	82.34%

Arbutus Biopharma has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	270.68	-$276.48M	-$1.57	N/A
Arbutus Biopharma	$14.08M	62.61	-$33.50M	$0.79	5.63

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Arbutus Biopharma had 10 more articles in the media than Relay Therapeutics. MarketBeat recorded 10 mentions for Arbutus Biopharma and 0 mentions for Relay Therapeutics. Arbutus Biopharma's average media sentiment score of 0.71 beat Relay Therapeutics' score of 0.51 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Relay Therapeutics	Positive
Arbutus Biopharma	Positive

Relay Therapeutics has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Summary

Arbutus Biopharma beats Relay Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Arbutus Biopharma compare to Legend Biotech?

Arbutus Biopharma (NASDAQ:ABUS) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

In the previous week, Arbutus Biopharma had 1 more articles in the media than Legend Biotech. MarketBeat recorded 10 mentions for Arbutus Biopharma and 9 mentions for Legend Biotech. Arbutus Biopharma's average media sentiment score of 0.71 beat Legend Biotech's score of 0.29 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arbutus Biopharma presently has a consensus target price of $5.00, indicating a potential upside of 12.36%. Legend Biotech has a consensus target price of $55.79, indicating a potential upside of 200.41%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53

Arbutus Biopharma has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	62.61	-$33.50M	$0.79	5.63
Legend Biotech	$1.03B	3.50	-$296.80M	-$0.25	N/A

Arbutus Biopharma has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Arbutus Biopharma has a net margin of 84.22% compared to Legend Biotech's net margin of -7.21%. Arbutus Biopharma's return on equity of 90.98% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Legend Biotech	-7.21%	-8.71%	-5.40%

Summary

Arbutus Biopharma beats Legend Biotech on 11 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Veracyte?

Arbutus Biopharma (NASDAQ:ABUS) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Veracyte has higher revenue and earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	62.61	-$33.50M	$0.79	5.63
Veracyte	$517.15M	7.12	$66.35M	$1.41	32.49

Arbutus Biopharma has a net margin of 84.22% compared to Veracyte's net margin of 20.37%. Arbutus Biopharma's return on equity of 90.98% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Veracyte	20.37%	9.26%	8.61%

Arbutus Biopharma has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market.

Arbutus Biopharma currently has a consensus price target of $5.00, indicating a potential upside of 12.36%. Veracyte has a consensus price target of $55.78, indicating a potential upside of 21.76%. Given Veracyte's stronger consensus rating and higher probable upside, analysts plainly believe Veracyte is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

43.8% of Arbutus Biopharma shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 1.6% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Arbutus Biopharma had 3 more articles in the media than Veracyte. MarketBeat recorded 10 mentions for Arbutus Biopharma and 7 mentions for Veracyte. Arbutus Biopharma's average media sentiment score of 0.71 beat Veracyte's score of -0.05 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Veracyte beats Arbutus Biopharma on 9 of the 17 factors compared between the two stocks.

How does Arbutus Biopharma compare to Xenon Pharmaceuticals?

Arbutus Biopharma (NASDAQ:ABUS) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Arbutus Biopharma has a net margin of 84.22% compared to Xenon Pharmaceuticals' net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Xenon Pharmaceuticals had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 18 mentions for Xenon Pharmaceuticals and 10 mentions for Arbutus Biopharma. Xenon Pharmaceuticals' average media sentiment score of 0.90 beat Arbutus Biopharma's score of 0.71 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arbutus Biopharma has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Arbutus Biopharma has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	62.61	-$33.50M	$0.79	5.63
Xenon Pharmaceuticals	$7.50M	490.05	-$345.91M	-$4.74	N/A

Arbutus Biopharma presently has a consensus price target of $5.00, indicating a potential upside of 12.36%. Xenon Pharmaceuticals has a consensus price target of $70.27, indicating a potential upside of 84.82%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Summary

Arbutus Biopharma beats Xenon Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Arbutus Biopharma compare to ACADIA Pharmaceuticals?

Arbutus Biopharma (NASDAQ:ABUS) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

ACADIA Pharmaceuticals has higher revenue and earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	62.61	-$33.50M	$0.79	5.63
ACADIA Pharmaceuticals	$1.07B	3.21	$391M	$2.22	8.99

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arbutus Biopharma has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Arbutus Biopharma has a net margin of 84.22% compared to ACADIA Pharmaceuticals' net margin of 33.42%. Arbutus Biopharma's return on equity of 90.98% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Arbutus Biopharma currently has a consensus price target of $5.00, indicating a potential upside of 12.36%. ACADIA Pharmaceuticals has a consensus price target of $32.76, indicating a potential upside of 64.23%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 18 mentions for ACADIA Pharmaceuticals and 10 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.71 beat ACADIA Pharmaceuticals' score of -0.17 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

ACADIA Pharmaceuticals beats Arbutus Biopharma on 11 of the 16 factors compared between the two stocks.

Get Arbutus Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABUS vs. The Competition

Export

Metric	Arbutus Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$882.58M	$3.84B	$7.13B	$13.32B
Dividend Yield	N/A	3.65%	2.53%	17.32%
P/E Ratio	5.64	13.12	274.76	26.04
Price / Sales	62.54	1,306.74	614.48	93.14
Price / Cash	N/A	39.04	27.22	34.69
Price / Book	11.11	16.99	11.13	6.35
Net Income	-$33.50M	-$23.20M	$3.50B	$381.35M
7 Day Performance	-8.54%	-2.86%	-1.88%	-0.70%
1 Month Performance	-13.69%	-10.77%	-6.20%	-4.58%
1 Year Performance	1.48%	19.01%	7.99%	1.51%

Arbutus Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABUS Arbutus Biopharma	2.166 of 5 stars	$4.45 -0.1%	$5.00 +12.5%	+1.6%	$882.58M	$14.08M	5.64	19	Gap Up
RLAY Relay Therapeutics	2.33 of 5 stars	$17.69 +1.3%	$25.92 +46.5%	+246.0%	$3.83B	$15.35M	N/A	192	Analyst Forecast
LEGN Legend Biotech	3.5506 of 5 stars	$18.62 -2.6%	$55.79 +199.6%	-42.1%	$3.70B	$1.03B	N/A	2,965	Gap Up
VCYT Veracyte	3.9867 of 5 stars	$45.23 -0.4%	$55.78 +23.3%	+27.3%	$3.65B	$517.15M	32.08	755
XENE Xenon Pharmaceuticals	3.7905 of 5 stars	$36.72 -0.6%	$70.27 +91.4%	-4.0%	$3.57B	$7.50M	N/A	370	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABUS) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arbutus Biopharma (ABUS) Competitors

ABUS vs. RLAY, LEGN, VCYT, XENE, and ACAD

How does Arbutus Biopharma compare to Relay Therapeutics?

Summary

How does Arbutus Biopharma compare to Legend Biotech?

Summary

How does Arbutus Biopharma compare to Veracyte?

Summary

How does Arbutus Biopharma compare to Xenon Pharmaceuticals?

Summary

How does Arbutus Biopharma compare to ACADIA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arbutus Biopharma (ABUS) Competitors

ABUS vs. RLAY, LEGN, VCYT, XENE, and ACAD

How does Arbutus Biopharma compare to Relay Therapeutics?

Do analysts rate RLAY or ABUS?

Is RLAY or ABUS more profitable?

Which has stronger earnings & valuation, RLAY or ABUS?

Do insiders and institutionals have more ownership in RLAY or ABUS?

Does the media prefer RLAY or ABUS?

Which has more risk and volatility, RLAY or ABUS?

Summary

How does Arbutus Biopharma compare to Legend Biotech?

Does the media favor ABUS or LEGN?

Do analysts rate ABUS or LEGN?

Which has preferable earnings & valuation, ABUS or LEGN?

Which has more risk & volatility, ABUS or LEGN?

Do insiders & institutionals believe in ABUS or LEGN?

Is ABUS or LEGN more profitable?

Summary

How does Arbutus Biopharma compare to Veracyte?

Which has stronger earnings & valuation, ABUS or VCYT?

Is ABUS or VCYT more profitable?

Which has more risk & volatility, ABUS or VCYT?

Do analysts recommend ABUS or VCYT?

Do institutionals and insiders have more ownership in ABUS or VCYT?

Does the media favor ABUS or VCYT?

Summary

How does Arbutus Biopharma compare to Xenon Pharmaceuticals?

Is ABUS or XENE more profitable?

Do institutionals & insiders believe in ABUS or XENE?

Does the media refer more to ABUS or XENE?

Which has more risk & volatility, ABUS or XENE?

Which has preferable earnings and valuation, ABUS or XENE?

Do analysts prefer ABUS or XENE?

Summary

How does Arbutus Biopharma compare to ACADIA Pharmaceuticals?

Which has stronger valuation & earnings, ABUS or ACAD?

Do institutionals and insiders believe in ABUS or ACAD?

Which has more volatility and risk, ABUS or ACAD?

Is ABUS or ACAD more profitable?

Do analysts recommend ABUS or ACAD?

Does the media prefer ABUS or ACAD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools